BridgeBio Pharma Return On Tangible Equity 2018-2024 | BBIO

BridgeBio Pharma return on tangible equity from 2018 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

BridgeBio Pharma Return On Tangible Equity 2018-2024 | BBIO

BridgeBio Pharma return on tangible equity from 2018 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19B
Dr Reddy's Laboratories (RDY)$12B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.1B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$434M
Personalis (PSNL)$261M
Assembly Biosciences (ASMB)$98M
Sol-Gel Technologies (SLGL)$12M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M